Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 22;188(3):320-327.
doi: 10.1093/bjd/ljac107.

Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review

Affiliations
Review

Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review

Piotr K Krajewski et al. Br J Dermatol. .

Abstract

Hidradenitis suppurativa (HS) is a chronic, recurrent, debilitating disorder of the pilosebaceous unit. Although its pathophysiology is not fully explained, inflammation seems to play an essential role in the development of HS. A link between obesity - often considered a state of chronic inflammation - and a higher prevalence of HS has been described. Nevertheless, the exact association is not well understood. Adipose tissue is a highly active endocrine organ that produces and secretes a variety of metabolically and immunologically active molecules called adipokines. The imbalances in concentrations of several adipokines in patients with HS have already been described. A shift towards the overproduction of proinflammatory adipokines (including leptin, resistin and visfatin) with the suppression of anti-inflammatory ones (adiponectin) has been noted. We conducted a review of the available data on adipokines in HS, concentrating on the described imbalances in adipokine concentrations, as well as possible implications in HS pathogenesis. Moreover, new, unstudied adipokines with possible implications in the development of HS are proposed.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest P.K.K. has participated in clinical trials for Celltrion, InfraRX, Janssen-Cilag, BMS and UCB. Ł.M. has been on advisory boards or acted as a consultant for AbbVie, Leo Pharma, Novartis and Pierre Fabre; has been a speaker for AbbVie, Janssen, Leo-Pharma, Novartis, Pierre Fabre and Valeant; and has participated in clinical trials for AbbVie, Almirall, Amgen, Bio-Thera, BMS, Celltrion, Galderma, Galapagos, Incyte, InfraRX, Janssen, Kiniksa, Medimmune, Menlo Therapeutics, Novartis, Pfizer, Regeneron, UCB, Teva and Trevi. J.C.S. has been on advisory boards or acted as a consultant for AbbVie, Leo Pharma, Novartis, Sandoz, Sanofi-Genzyme, Trevi and Viofor; has been a speaker for AbbVie, Janssen-Cilag, Eli-Lilly, Leo-Pharma and Sanofi-Genzyme; and has participated in clinical trials for AbbVie, Amgen, BMS, Galderma, Galapagos, Incyte, InfraRX, Janssen-Cilag, Menlo Therapeutics, Merck, Novartis, Pfizer, Regeneron, UCB and Trevi